Galaxy Surfactants Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Galaxy Surfactants Ltd trades at ₹1,926, in a downtrend and 43 weeks into that stage. That is −2.2% against its own 200-day average. It sits at 41% of a 52-week range of ₹1,597 to ₹2,406. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 8 straight weeks.

Today the stock is in a downtrend — week 43 of stage 4, confirmed. At ₹1,926 it trades −2.2% versus its 200-day average and sits at 41% of its 52-week range (₹1,597–₹2,406).

Against the market, two honest reads. Cumulative: over the last 8.4 years the stock moved +16% while the NIFTY 500 moved +150% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 8 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 29th percentile of its own range.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Galaxy Surfactants Ltd trades at 24.8× P/E, near the bottom of its own range — cheaper only 29% of the time. Its long-run median P/E is 26.9×, measured across 8.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 24.8× is near the bottom of its own range — cheaper only 29% of the time, against a long-run median of 26.9× measured over 8.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved −12.3% against a −24.4% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −9.3%/yr price move, ~−1.7%/yr came from earnings growth and ~−7.6 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Galaxy Surfactants Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −13.1% latest against +24.5% at its 12-quarter best), ROCE slipping at 13.6%. The read is built from 12 quarters across 4 curves, on full evidence.

🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

41.0/100 — rank 22 of 27 in Speciality Chemicals · 90% evidence confidence

Galaxy Surfactants Ltd scores 41.0 out of 100 against the 27 companies it is compared with in Speciality Chemicals, ranking 22. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 12.3 + 13.8 + 8.7 + 6.2 = 41. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Galaxy Surfactants Ltd reported ₹1,315 Cr of revenue in the Mar 26 quarter, +14.8% year on year. That is the 8th straight quarter of year-on-year growth. Over 10 years it has compounded at 11.3% a year. The last full year, FY26, came in at ₹5,245 Cr. The last four reported quarters add to ₹5,248 Cr.

Galaxy Surfactants Ltd reported ₹1,315 Cr of revenue in the Mar 26 quarter, +14.8% year on year. That is the 8th straight quarter of year-on-year growth. Over 10 years it has compounded at 11.3% a year. The last full year, FY26, came in at ₹5,245 Cr. The last four reported quarters add to ₹5,248 Cr.

FY26 revenue came in at ₹5,245 Cr (+24.3% on the year), capping 10 years at 11.3% compound. The latest quarter (Mar 26) printed ₹1,315 Cr, +14.8% year on year — the 8th consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +24.6% growth against the decade's 11.3% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +24.2% over the last 4 quarters against +17.6%/yr over the last 8 — accelerating; TTM profit −13.1% vs −6.0%/yr — rolling over.

→ Revenue grew — did margins hold as it scaled? Next: 9.0% this quarter (−2.0 pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Galaxy Surfactants Ltd's operating margin is 9.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 9.0% to 16.0%. The current quarter sits inside that band.

Galaxy Surfactants Ltd's operating margin is 9.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 9.0% to 16.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 9.0%, −2.0 pp against the same quarter a year ago. Across 12 fiscal years the operating margin has ranged 9.0%–16.0%.

🚨 Why the margin moved: operating margin went −1.8 pp year on year while gross margin went −3.6 pp — the loss came mostly from the gross line: input costs and pricing.

→ Margins slipped — did that reach the bottom line? Next: profit −18.4% in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Galaxy Surfactants Ltd earned ₹62.0 Cr of net profit in the Mar 26 quarter, −18.4% year on year. Full-year FY26 profit was ₹267 Cr. The 10-year compound rate is 10.0%. That is 4.7% of the quarter's revenue. The same quarter a year earlier earned ₹76.0 Cr.

Galaxy Surfactants Ltd earned ₹62.0 Cr of net profit in the Mar 26 quarter, −18.4% year on year. Full-year FY26 profit was ₹267 Cr. The 10-year compound rate is 10.0%. That is 4.7% of the quarter's revenue. The same quarter a year earlier earned ₹76.0 Cr.

Mar 26 profit was ₹62.0 Cr, −18.4% year on year. On the full year, FY26 printed ₹267 Cr (−12.5%), and the 10-year compound rate is 10.0%.

🚨 Why profit moved: revenue contributed +14.8% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.

Pace comparison, last four quarters: profit −12.8% vs revenue +24.6%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.

→ Profit rose — but did the cash follow? Next: 146% of the last 3 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 146% of Galaxy Surfactants Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹333 Cr of operating cash against ₹267 Cr of profit. After ₹186 Cr of capital spending, ₹147 Cr was left as free cash.

FY26: operating cash of ₹333 Cr against reported profit of ₹267 Cr, leaving free cash of ₹147 Cr after ₹186 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 146% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 146%: the cash cycle held roughly steady between FY21 and FY26 — so conversion tracks profitability rather than the cycle.

Router verdict: the bigger cash user is investment — capital spending ran 1.9× depreciation over three years, so the next section's job is to check what that build-out is buying.

→ So follow the cash to where it goes. Next: ₹626 Cr of building over 3 years.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Galaxy Surfactants Ltd's cash conversion cycle runs 66 days in FY26, down from 72 days in FY21. Capital spending ran ₹626 Cr over the last 3 years. At FY26 sales of ₹5,245 Cr each day of that cycle holds about ₹14.4 Cr, so roughly ₹948 Cr sits inside the business at any moment.

FY26: debtors at 52 days, inventory at 76 days — roughly 2.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 66 days, tighter than FY21's 72.

The full loop: cash goes out to suppliers and production on day 0; stock waits 76 days to sell; customers pay about 52 days after that; and suppliers themselves are paid at 62 days — netting out to the 66-day cycle.

In money terms: at FY26 sales of ₹5,245 Cr, each day of the cycle holds about ₹14.4 Cr — so the 66-day loop keeps roughly ₹948 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹626 Cr over the last 3 fiscal years against ₹333 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹181 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 14% and the ROIC − WACC spread is +1.0 pp.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Galaxy Surfactants Ltd earns a ROCE of 14% in FY26. Return on invested capital clears the cost of that capital by +1.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 5.1% net margin on 1.36× asset turns.

FY26 ROCE is 14%.

Why the return is what it is — the wiring (FY26): 5.1% net margin × 1.36× asset turns × 1.41× balance-sheet leverage ≈ 9.8% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 13.0% − 12.0% = a +1.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Positive but thin — value creation with little room for error.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.09.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Galaxy Surfactants Ltd carries total debt of ₹235 Cr against shareholder equity of ₹2,745 Cr as of Mar 26, a debt-to-equity of 0.09 — effectively unlevered. On the annual view that ratio went from 0.27 in FY22 to 0.09 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹235 Cr against shareholder equity of ₹2,745 Cr — a debt-to-equity of 0.09. On the annual view, debt-to-equity went from 0.27 (FY22) to 0.09 (FY26). The returns on this page are earned, not borrowed.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Galaxy Surfactants Ltd moved a full percentage point over the last two years — the register is quiet. Foreign institutions moved −0.1 points over the same window, to 3.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +0.8 points over 8 quarters to 13.5%; Foreign institutions: −0.1 points over 8 quarters to 3.8%; Promoters: +0.0 points over 8 quarters to 70.9%.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Galaxy Surfactants Ltd: the Z-score reads 7.08. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 7.08 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 7.08.

Frequently asked questions